Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
В каких клинических ситуациях целесообразно выбрать фиксированную комбинацию b-адреноблокатора и дигидропиридинового антагониста кальция в терапии артериальной гипертонии - Журнал Системные Гипертензии №4 (2010)
В каких клинических ситуациях целесообразно выбрать фиксированную комбинацию b-адреноблокатора и дигидропиридинового антагониста кальция в терапии артериальной гипертонии
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В обзоре представлены данные об эффективности терапии метопрололом сукцинатом и фелодипином, которые демонстрируют хорошую антигипертензивную эффективность и безопасность лечения этими препаратами.
Ключевые слова: артериальная гипертония, β-блокаторы, антагонисты кальция.
Key words: arterial hypertension, β-blockers, calcium antagonists.
Ключевые слова: артериальная гипертония, β-блокаторы, антагонисты кальция.
________________________________________________
Key words: arterial hypertension, β-blockers, calcium antagonists.
Полный текст
Список литературы
1. Gillman M, Kannel W, Belanger A, D’Agostino R. Influence of heart rate on mortality among persons with hypertension: the Framingham Study. Am Heart J 1993; 125: 1148–54.
2. Singh BN. Morbidity and mortality in cardiovascular disorders: impact of reduced heart rate. J Cardiovasc Pharmacol Ther 2001; 6 (4): 313–33.
3. Kaplan N, Opie LH. Antihypertensive drugs. In: Opie L (ed.). Drugs for the heart, 4 ed. Philadelphia, 1995.
4. McInnes GT. Hypertension and coronary artery disease: cause and effect. J Hypertens 1995; 13 (suppl. 2): 49–56.
5. Julius S. Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. Eur Heart J 1998; 19 (suppl. F): 14–8.
6. Fung JW, Yu CM, Kum LC et al. Role of beta-blocker therapy in heart failure and atrial fibrillation. Card Electrophysiol Rev 2003; 7 (3): 236–42.
7. Rumantir MS, Vaz M, Esler MD. Neural mechanisms in human obesity-related hypertension. J Hypertens 1999; 1125–33.
8. Ezzati M, Hoorn SV, Rodgers A et al. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 2003; 362: 271–80.
9. Jonas M, Reicher-Reiss H, Boyko V et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. Am J Cardiol 1996; 77: 1273–7.
10. Hedblad B, Wikstrand J, Janzon L et al. Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptom-atic Plaque Study (BCAPS). Circulation 2001; 103: 1721–6.
11. Omvik P et al. Equal efficacy and improved tolerability with 50 mg controlled-release metoprolol compared with 100 mg conventional metoprolol in hypertensive patients. Am J Ther 1994; 1: 65–73.
12. Dahlof B, Hansson L, Lindholm LH et al. Swedish trial in old patients with hypertension (STOP-Hypertension): analyses performed up to l992. Clin Exp Hypertension 1993; 15: 925–39.
13. Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). Lancet 1991; 338: 1281–5.
14. Ekbom T, Linjer E, Hedner T et al. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2. Blood Press 2004; 13: 137–41
15. Hansson L, Dahlof B, Ekbom T et al. Key learnings from the STOP Hypertension study: an update on the progress of the ongoing Swedish study of antihypertensive treatment in the elderly. Cardiovasc Drug Ther 1990; 4: 1253–6.
16. Johannesson M, Dahlof B, Lindholm LH et al. The costeffectiveness of treating hypertension in elderly people an analysis of the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). J Intern Med 1993; 234: 317–23.
17. Smith SA, Mace PJ, Littler WA. Felodipine, blood pressure, and cardiovascular reflexes in hypertensive humans. Hypertension 1986; 8: 1172–8.
18. Gelal A, Balkan D, Ozzeybek D et al. Effect of menthol on the pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacology 2005; 60: 785–90.
19. Izzedine H, Launay-Vacher V, Deray G, Hulot JS. Nelfinavir and felodipine: a cytochrome P450 3A4-mediated drug interaction. Clin Pharmacol Ther 2004; 75: 362–3.
20. Miglioranca LH, Barrientos-Astigarraga RE, Schug BS. Felodipine quantification in human plasma by high-performance liquid chromatography coupled to tandem mass spectrometry. J Chromatogr. B. Analyt Technol Biomed Life Sci 2005; 25: 217–23.
21. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755–62.
22. Trenkwalder P, Elmfelolt D. Improving the therapeutic balance between efficacy and tolerability in antihypertensive drugs – felodipine and metaprolol. J Hum Hypertension 1995; 9 (Suppl. 2): 37–42.
23. Чазова И.Е., Мычка В.Б., Горностаев В.В. Эффективность и безопасность применения комбинированного препарата Логимакс у больных с мягкой и умеренной артериальной гипертензией и сахарным диабетом типа 2. Артер. гипертенз. 2002; 3: 103–6.
2. Singh BN. Morbidity and mortality in cardiovascular disorders: impact of reduced heart rate. J Cardiovasc Pharmacol Ther 2001; 6 (4): 313–33.
3. Kaplan N, Opie LH. Antihypertensive drugs. In: Opie L (ed.). Drugs for the heart, 4 ed. Philadelphia, 1995.
4. McInnes GT. Hypertension and coronary artery disease: cause and effect. J Hypertens 1995; 13 (suppl. 2): 49–56.
5. Julius S. Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. Eur Heart J 1998; 19 (suppl. F): 14–8.
6. Fung JW, Yu CM, Kum LC et al. Role of beta-blocker therapy in heart failure and atrial fibrillation. Card Electrophysiol Rev 2003; 7 (3): 236–42.
7. Rumantir MS, Vaz M, Esler MD. Neural mechanisms in human obesity-related hypertension. J Hypertens 1999; 1125–33.
8. Ezzati M, Hoorn SV, Rodgers A et al. Estimates of global and regional potential health gains from reducing multiple major risk factors. Lancet 2003; 362: 271–80.
9. Jonas M, Reicher-Reiss H, Boyko V et al. Usefulness of beta-blocker therapy in patients with non-insulin-dependent diabetes mellitus and coronary artery disease. Bezafibrate Infarction Prevention (BIP) Study Group. Am J Cardiol 1996; 77: 1273–7.
10. Hedblad B, Wikstrand J, Janzon L et al. Low dose metoprolol CR/XL and fluvastatin slow progression of carotid intima-media thickness: main results from the Beta-Blocker Cholesterol-Lowering Asymptom-atic Plaque Study (BCAPS). Circulation 2001; 103: 1721–6.
11. Omvik P et al. Equal efficacy and improved tolerability with 50 mg controlled-release metoprolol compared with 100 mg conventional metoprolol in hypertensive patients. Am J Ther 1994; 1: 65–73.
12. Dahlof B, Hansson L, Lindholm LH et al. Swedish trial in old patients with hypertension (STOP-Hypertension): analyses performed up to l992. Clin Exp Hypertension 1993; 15: 925–39.
13. Dahlof B, Lindholm LH, Hansson L et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP Hypertension). Lancet 1991; 338: 1281–5.
14. Ekbom T, Linjer E, Hedner T et al. Cardiovascular events in elderly patients with isolated systolic hypertension. A subgroup analysis of treatment strategies in STOP-Hypertension-2. Blood Press 2004; 13: 137–41
15. Hansson L, Dahlof B, Ekbom T et al. Key learnings from the STOP Hypertension study: an update on the progress of the ongoing Swedish study of antihypertensive treatment in the elderly. Cardiovasc Drug Ther 1990; 4: 1253–6.
16. Johannesson M, Dahlof B, Lindholm LH et al. The costeffectiveness of treating hypertension in elderly people an analysis of the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). J Intern Med 1993; 234: 317–23.
17. Smith SA, Mace PJ, Littler WA. Felodipine, blood pressure, and cardiovascular reflexes in hypertensive humans. Hypertension 1986; 8: 1172–8.
18. Gelal A, Balkan D, Ozzeybek D et al. Effect of menthol on the pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacology 2005; 60: 785–90.
19. Izzedine H, Launay-Vacher V, Deray G, Hulot JS. Nelfinavir and felodipine: a cytochrome P450 3A4-mediated drug interaction. Clin Pharmacol Ther 2004; 75: 362–3.
20. Miglioranca LH, Barrientos-Astigarraga RE, Schug BS. Felodipine quantification in human plasma by high-performance liquid chromatography coupled to tandem mass spectrometry. J Chromatogr. B. Analyt Technol Biomed Life Sci 2005; 25: 217–23.
21. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 1998; 351: 1755–62.
22. Trenkwalder P, Elmfelolt D. Improving the therapeutic balance between efficacy and tolerability in antihypertensive drugs – felodipine and metaprolol. J Hum Hypertension 1995; 9 (Suppl. 2): 37–42.
23. Чазова И.Е., Мычка В.Б., Горностаев В.В. Эффективность и безопасность применения комбинированного препарата Логимакс у больных с мягкой и умеренной артериальной гипертензией и сахарным диабетом типа 2. Артер. гипертенз. 2002; 3: 103–6.
Авторы
И.Е.Чазова, Л.Г.Ратова
ФГУ Российский кардиологический научно-производственный комплекс Минздравсоцразвития
FS1 Russian cardiology scientific and production complex, Moscow
ФГУ Российский кардиологический научно-производственный комплекс Минздравсоцразвития
________________________________________________
FS1 Russian cardiology scientific and production complex, Moscow
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.